These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2199402)

  • 1. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study.
    Trump DL; Marsh JC; Kvols LK; Citrin D; Davis TE; Hahn RG; Vogl SE
    Invest New Drugs; 1990; 8 Suppl 1():S91-4. PubMed ID: 2199402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
    Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
    J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin in advanced hormone refractory prostatic cancer patients.
    Canobbio L; Guarneri D; Miglietta L; Decensi A; Oneto F; Boccardo F
    Eur J Cancer; 1993; 29A(15):2094-6. PubMed ID: 7507687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group.
    Trump DL; Elson P; Madajewicz S; Dickman SH; Hahn RG; Harris JE; Vogl SE
    J Urol; 1990 Nov; 144(5):1119-22. PubMed ID: 2231883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study).
    Arseneau J; Blessing JA; Stehman FB; McGehee R
    Invest New Drugs; 1986; 4(2):187-91. PubMed ID: 3525449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer.
    Olver IN; Stephenson J; Schulze D
    Cancer Chemother Pharmacol; 2000; 46(4):338-41. PubMed ID: 11052632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
    J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial.
    Witte RS; Yeap BY; Trump DL
    Invest New Drugs; 1994; 12(3):255-8. PubMed ID: 7896546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
    Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
    Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose carboplatin in refractory ovarian cancer patients.
    Ozols RF; Ostchega Y; Curt G; Young RC
    J Clin Oncol; 1987 Feb; 5(2):197-201. PubMed ID: 3543243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
    Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
    Curt GA; Grygiel JJ; Corden BJ; Ozols RF; Weiss RB; Tell DT; Myers CE; Collins JM
    Cancer Res; 1983 Sep; 43(9):4470-3. PubMed ID: 6347373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
    Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
    Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin therapy in advanced endometrial cancer.
    Green JB; Green S; Alberts DS; O'Toole R; Surwit EA; Noltimier JW
    Obstet Gynecol; 1990 Apr; 75(4):696-700. PubMed ID: 2179783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
    Kuzel TM; Tallman MS; Shevrin D; Braud E; Kilton L; Johnson P; Kozlowski J; Vogelzang NJ; Blough R; Benson AB
    Cancer; 1993 Sep; 72(6):1965-8. PubMed ID: 8364875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.